{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T10:36:53Z","timestamp":1770460613014,"version":"3.49.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,9,14]],"date-time":"2021-09-14T00:00:00Z","timestamp":1631577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,9,14]],"date-time":"2021-09-14T00:00:00Z","timestamp":1631577600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1007\/s00520-021-06548-4","type":"journal-article","created":{"date-parts":[[2021,9,14]],"date-time":"2021-09-14T13:02:57Z","timestamp":1631624577000},"page":"989-994","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Biologic therapies for checkpoint inhibitor-induced cutaneous toxicities: a single-institution study of 17 consecutively treated patients"],"prefix":"10.1007","volume":"30","author":[{"given":"Jonathan J.","family":"Lo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meghan M.","family":"Heberton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omar","family":"Pacha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Auris O.","family":"Huen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anisha B.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,9,14]]},"reference":[{"issue":"2","key":"6548_CR1","doi-asserted-by":"publisher","first-page":"154","DOI":"10.4103\/apjon.apjon_3_19","volume":"6","author":"N La-Beck","year":"2019","unstructured":"La-Beck N, Trinh S, Le A, Gowani S (2019) Management of immune-related adverse events associated with immune checkpoint inhibitor therapy: a mini review of current clinical guidelines. Asia Pac J Oncol Nurs 6(2):154. https:\/\/doi.org\/10.4103\/apjon.apjon_3_19","journal-title":"Asia Pac J Oncol Nurs"},{"issue":"5","key":"6548_CR2","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/s1470-2045(15)70122-1","volume":"16","author":"A Eggermont","year":"2015","unstructured":"Eggermont A, Chiarion-Sileni V, Grob J et al (2015) Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol 16(5):522\u2013530. https:\/\/doi.org\/10.1016\/s1470-2045(15)70122-1","journal-title":"Lancet Oncol"},{"issue":"8","key":"6548_CR3","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/nejmoa1003466","volume":"363","author":"F Hodi","year":"2010","unstructured":"Hodi F, O\u2019Day S, McDermott D et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363(8):711\u2013723. https:\/\/doi.org\/10.1056\/nejmoa1003466","journal-title":"N Engl J Med"},{"issue":"1","key":"6548_CR4","first-page":"123","volume":"93","author":"IW Tattersall","year":"2020","unstructured":"Tattersall IW, Leventhal JS (2020) Cutaneous toxicities of immune checkpoint inhibitors: the role of the dermatologist. Yale J Biol Med 93(1):123\u2013132","journal-title":"Yale J Biol Med"},{"key":"6548_CR5","doi-asserted-by":"publisher","unstructured":"Muntyanu A, Netchiporouk E, Gerstein W, Gniadecki R, Litvinov I (2021) Cutaneous immune-related adverse events (irAEs) to immune checkpoint inhibitors: a dermatology perspective on management. J Cutan Med Surg 25(1):59\u201376.\u00a0https:\/\/doi.org\/10.1177\/1203475420943260","DOI":"10.1177\/1203475420943260"},{"issue":"6","key":"6548_CR6","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1158\/2326-6066.cir-18-0682","volume":"7","author":"D Johnson","year":"2019","unstructured":"Johnson D, Patel A, Uemura M et al (2019) IL17A blockade successfully treated psoriasiform dermatologic toxicity from immunotherapy. Cancer Immunol Res 7(6):860\u2013865. https:\/\/doi.org\/10.1158\/2326-6066.cir-18-0682","journal-title":"Cancer Immunol Res"},{"issue":"6","key":"6548_CR7","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/j.jaad.2018.07.008","volume":"79","author":"J Siegel","year":"2018","unstructured":"Siegel J, Totonchy M, Damsky W et al (2018) Bullous disorders associated with anti\u2013PD-1 and anti\u2013PD-L1 therapy: a retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy. J Am Acad Dermatol 79(6):1081\u20131088. https:\/\/doi.org\/10.1016\/j.jaad.2018.07.008","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"6548_CR8","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1016\/j.jaad.2018.10.062","volume":"80","author":"E Coleman","year":"2019","unstructured":"Coleman E, Ko C, Dai F, Tomayko M, Kluger H, Leventhal J (2019) Inflammatory eruptions associated with immune checkpoint inhibitor therapy: a single-institution retrospective analysis with stratification of reactions by toxicity and implications for management. J Am Acad Dermatol 80(4):990\u2013997. https:\/\/doi.org\/10.1016\/j.jaad.2018.10.062","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"6548_CR9","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.jdcr.2016.05.009","volume":"2","author":"W Damsky","year":"2016","unstructured":"Damsky W, Kole L, Tomayko M (2016) Development of bullous pemphigoid during nivolumab therapy. JAAD Case Rep 2(6):442\u2013444. https:\/\/doi.org\/10.1016\/j.jdcr.2016.05.009","journal-title":"JAAD Case Rep"},{"key":"6548_CR10","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.5824","author":"E Monsour","year":"2019","unstructured":"Monsour E, Pothen J, Balaraman R (2019) A novel approach to the treatment of pembrolizumab-induced psoriasis exacerbation: a case report. Cureus. https:\/\/doi.org\/10.7759\/cureus.5824","journal-title":"Cureus"},{"issue":"6","key":"6548_CR11","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1001\/jamadermatol.2017.0091","volume":"153","author":"L Sowerby","year":"2017","unstructured":"Sowerby L, Dewan AK, Granter S, Gandhi L, LeBoeuf NR (2017) Rituximab treatment of nivolumab-induced bullous pemphigoid. JAMA Dermatol 153(6):603\u2013605. https:\/\/doi.org\/10.1001\/jamadermatol.2017.0091","journal-title":"JAMA Dermatol"},{"key":"6548_CR12","doi-asserted-by":"publisher","first-page":"100031","DOI":"10.1016\/j.cpccr.2020.100031","volume":"2","author":"M Mihailescu","year":"2020","unstructured":"Mihailescu M, Brockstein B, Desai N, Waldinger J (2020) Successful reintroduction and continuation of nivolumab in a patient with immune checkpoint inhibitor-induced bullous pemphigoid. Curr. Probl. Cancer: Case Rep. 2:100031. https:\/\/doi.org\/10.1016\/j.cpccr.2020.100031","journal-title":"Curr. Probl. Cancer: Case Rep."},{"issue":"1","key":"6548_CR13","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s40425-019-0613-1","volume":"7","author":"W Damsky","year":"2019","unstructured":"Damsky W, Jilaveanu L, Turner N et al (2019) B cell depletion or absence does not impede anti-tumor activity of PD-1 inhibitors. J Immunother Cancer 7(1):153. https:\/\/doi.org\/10.1186\/s40425-019-0613-1","journal-title":"J Immunother Cancer"},{"issue":"20","key":"6548_CR14","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1056\/NEJMc1703047","volume":"376","author":"K Esfahani","year":"2017","unstructured":"Esfahani K, Miller WH Jr (2017) Reversal of autoimmune toxicity and loss of tumor response by interleukin-17 blockade. N Engl J Med 376(20):1989\u20131991. https:\/\/doi.org\/10.1056\/NEJMc1703047","journal-title":"N Engl J Med"},{"issue":"30","key":"6548_CR15","doi-asserted-by":"publisher","first-page":"2746","DOI":"10.1200\/JCO.18.02141","volume":"37","author":"GS Phillips","year":"2019","unstructured":"Phillips GS, Wu J, Hellmann MD et al (2019) Treatment outcomes of immune-related cutaneous adverse events. J Clin Oncol 37(30):2746\u20132758. https:\/\/doi.org\/10.1200\/JCO.18.02141","journal-title":"J Clin Oncol"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-021-06548-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-021-06548-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-021-06548-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,4]],"date-time":"2022-01-04T09:12:32Z","timestamp":1641287552000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-021-06548-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,14]]},"references-count":15,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["6548"],"URL":"https:\/\/doi.org\/10.1007\/s00520-021-06548-4","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,14]]},"assertion":[{"value":"21 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Study was approved and conducted under institutional review board protocol.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"N\/A","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"N\/A","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors report no conflicts of interest. This study has not been presented or published previously.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}